Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burfiralimab in moderate to severe RA
NCT06306339Phase 2Not yet recruiting
- Sponsor
- ImmuneMed Inc.
- Start
- Mar 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of burfiralimab in rheumatoid arthritis (RA), sponsored by ImmuneMed Inc.. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
burfiralimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06306339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06306339.